Reopening schools safely and educating youth (ROSSEY) study : Protocol for a community-based, cluster randomized controlled trial
Copyright © 2023. Published by Elsevier Inc..
INTRODUCTION: ROSSEY is a community-academic partnership aiming to develop and test a COVID-19 risk communication intervention for elementary school students and families in Yakima County, Washington. We describe the ROSSEY study protocol that will be implemented in the Yakima School District.
METHODS: Aim 1 is to identify the community's social, ethical, and behavioral needs and resources for students to return to school and maintain onsite learning. We will conduct semi-structured interviews with students and school employees and focus groups with parents. Aim 2 is to evaluate the effectiveness of risk communication on students' school attendance. We will conduct a cluster randomized control trial. We will enroll 14 Yakima School District elementary schools with 900 student participants and randomize the schools into the COVID-19 risk communication intervention or control group. Aim 3 will assess implementation of the risk communication intervention and schools' COVID-19 mitigation strategies. We will use the RE-AIM framework to guide this work, which will entail conducting semi-structured interviews with students and school employees and focus groups with parents.
DISCUSSION: Implementation of science-based risk communication can educate the community on the benefits and safety of COVID-19 testing and vaccination. Risk communication may also inform families about the role of COVID-19 testing and vaccines as part of mitigation strategies to allow for safe in-person learning. Schools have extraordinary influence to promote children's health through policy and practice change. Study findings will provide evidence to facilitate policy decisions and best practices at schools that facilitate adoption of COVID-19 risk communication.
TRIAL REGISTRATION: ClinicalTrials.govNCT04859699. Registered on April 26, 2021.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:139 |
|---|---|
| Enthalten in: |
Contemporary clinical trials - 139(2024) vom: 01. Apr., Seite 107480 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ramirez, Magaly [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
COVID-19 testing |
|---|
| Anmerkungen: |
Date Completed 25.03.2024 Date Revised 05.04.2024 published: Print-Electronic ClinicalTrials.gov: NCT04859699 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cct.2024.107480 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36872834X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36872834X | ||
| 003 | DE-627 | ||
| 005 | 20240405233614.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240222s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cct.2024.107480 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1366.xml |
| 035 | |a (DE-627)NLM36872834X | ||
| 035 | |a (NLM)38382823 | ||
| 035 | |a (PII)S1551-7144(24)00054-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ramirez, Magaly |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Reopening schools safely and educating youth (ROSSEY) study |b Protocol for a community-based, cluster randomized controlled trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.03.2024 | ||
| 500 | |a Date Revised 05.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT04859699 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier Inc. | ||
| 520 | |a INTRODUCTION: ROSSEY is a community-academic partnership aiming to develop and test a COVID-19 risk communication intervention for elementary school students and families in Yakima County, Washington. We describe the ROSSEY study protocol that will be implemented in the Yakima School District | ||
| 520 | |a METHODS: Aim 1 is to identify the community's social, ethical, and behavioral needs and resources for students to return to school and maintain onsite learning. We will conduct semi-structured interviews with students and school employees and focus groups with parents. Aim 2 is to evaluate the effectiveness of risk communication on students' school attendance. We will conduct a cluster randomized control trial. We will enroll 14 Yakima School District elementary schools with 900 student participants and randomize the schools into the COVID-19 risk communication intervention or control group. Aim 3 will assess implementation of the risk communication intervention and schools' COVID-19 mitigation strategies. We will use the RE-AIM framework to guide this work, which will entail conducting semi-structured interviews with students and school employees and focus groups with parents | ||
| 520 | |a DISCUSSION: Implementation of science-based risk communication can educate the community on the benefits and safety of COVID-19 testing and vaccination. Risk communication may also inform families about the role of COVID-19 testing and vaccines as part of mitigation strategies to allow for safe in-person learning. Schools have extraordinary influence to promote children's health through policy and practice change. Study findings will provide evidence to facilitate policy decisions and best practices at schools that facilitate adoption of COVID-19 risk communication | ||
| 520 | |a TRIAL REGISTRATION: ClinicalTrials.govNCT04859699. Registered on April 26, 2021 | ||
| 650 | 4 | |a Clinical Trial Protocol | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 testing | |
| 650 | 4 | |a Child health | |
| 650 | 4 | |a Communication | |
| 650 | 4 | |a Hispanic or Latino | |
| 650 | 4 | |a School health services | |
| 700 | 1 | |a Shah, Parth D |e verfasserin |4 aut | |
| 700 | 1 | |a Chu, Helen Y |e verfasserin |4 aut | |
| 700 | 1 | |a Garza, Lorenzo |e verfasserin |4 aut | |
| 700 | 1 | |a Linde, Sandra |e verfasserin |4 aut | |
| 700 | 1 | |a Garrison, Michelle M |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Chuan |e verfasserin |4 aut | |
| 700 | 1 | |a Bishop, Sonia |e verfasserin |4 aut | |
| 700 | 1 | |a Ibarra, Genoveva |e verfasserin |4 aut | |
| 700 | 1 | |a Ko, Linda K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Contemporary clinical trials |d 2005 |g 139(2024) vom: 01. Apr., Seite 107480 |w (DE-627)NLM154869031 |x 1559-2030 |7 nnns |
| 773 | 1 | 8 | |g volume:139 |g year:2024 |g day:01 |g month:04 |g pages:107480 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cct.2024.107480 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 139 |j 2024 |b 01 |c 04 |h 107480 | ||